Azitra, Inc. (NYSE American: AZTR) has announced that its Co-founder and Chief Operating Officer, Travis Whitfill, Ph.D., MPH, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled to take place from September 14 to September 16, 2026, in New York City.
According to the filing, Dr. Whitfill will provide an update on the company's recent progress and key pipeline activities during the prerecorded presentation. The update will include initial data from the ATR-COSF program, which supports the company's strategy to leverage its microbial genetic engineering platform for cosmetic applications, specifically targeting fine lines and wrinkles.
In addition to the general presentation, Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners. These meetings are intended to highlight Azitra’s business strategy, recent corporate achievements, and anticipated milestones.
Azitra is a clinical-stage biopharmaceutical company focused on precision dermatology and high-value cosmetic proteins and peptides. The company’s portfolio includes ATR-COSF, a recombinant protein technology designed for cosmetic and skincare applications, and ATR-04, an investigational live biotherapeutic for EGFR inhibitor-associated rash. Azitra has received Fast Track designation from the FDA for the ATR-04 program, which impacts approximately 150,000 people in the United States.
